Pharsight

Rhofade generic

Rhofade is an FDA-approved drug owned by Epi Hlth. First authorized for market use on 18th January 2017, it contains the active ingredient oxymetazoline hydrochloride and is available in cream format for topical use. Currently, Rhofade holds 8 patents; none of which have expired yet.

When will Rhofade generic be available?

While Rhofade is yet to have an available generic version, the possibility for a generic release begins after 11th June 2035. This is subsequent to the expiry of its last patent on the same date, unless there is a successful Para IV filing.

Rhofade uses

Rhofade is primarily used as a once-daily topical treatment of persistent facial erythema associated with rosacea in adults. Its active ingredient, oxymetazoline hydrochloride, plays a vital role in managing this condition. It is also prescribed to female adults experiencing no rebound or worsening of facial erythema post-treatment.

Rhofade patent expiration

Rhofade currently has eight active patents, the most recent of which focuses on stabilized Oxymetazoline formulations and their uses. The last Rhofade generic patent is due to expire on 11th June 2035. Below are the details of the patents:

Rhofade dosage

Want to ask something?